Ani Pharmaceuticals (ANIP) Cash from Investing Activities Growth (3y) (2013 - 2026)
Powered by 
Analysis
Ani Pharmaceuticals (ANIP) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.60 Bn | 38.94 Bn | 2.15 Bn | -53.63% |
| 2 | Viatris | 19.15 Bn | 18.27 Bn | 1.46 Bn | 15.92% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 33.96% |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn | -115.39% |
| 5 | Bausch Health Companies | 2.35 Bn | 516.55 Mn | 2.10 Bn | -45.81% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 23.52% |
| 8 | Amphastar Pharmaceuticals | 996.17 Mn | 706.05 Mn | 93.47 Mn | 27.82% |
| 9 | Fennec Pharmaceuticals | 404.39 Mn | 363.15 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.52% |
| Mar 31, 2026 | -68.83% |
| Dec 31, 2025 | 23.57% |
| Sep 30, 2025 | 14.37% |
| Jun 30, 2025 | -125.32% |
| Mar 31, 2025 | -108.87% |
| Dec 31, 2024 | 49.35% |
| Sep 30, 2024 | -780.90% |
| Jun 30, 2024 | 41.26% |
| Mar 31, 2024 | 141.71% |
| Dec 31, 2023 | -31.14% |
| Sep 30, 2023 | 7.80% |
| Jun 30, 2023 | -33.83% |
| Mar 31, 2023 | 65.55% |
| Dec 31, 2022 | -31.75% |
| Sep 30, 2022 | -71.90% |
| Jun 30, 2022 | 46.56% |
| Mar 31, 2022 | 52.47% |
| Dec 31, 2021 | -486.74% |
| Sep 30, 2021 | 68.38% |